Short answer
Alkermes plc. (ALKS) filed an 8-K current report with the SEC on September 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). September 21, 2026 press release disclosed positive topline results.
Alkermes plc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- September 21, 2026 press release disclosed positive topline results
- Market relevance depends on the referenced study, endpoint, and product details in the accompanying exhibit
Item 8.01 · Other Events
- Positive topline Phase 1 proof-of-concept results for investigational ADHD therapy ALKS 7290
- Orexin 2 receptor agonist mechanism expands Alkermes’ pipeline beyond existing commercial products
- Early-stage data may support additional clinical development, but efficacy and safety validation remain ahead
Item EX-99.1 · Exhibit EX-99.1
- Phase 1b proof-of-concept supports ALKS 7290 as a differentiated, first-in-class OX2R agonist for adult ADHD
- AISRS median reductions at day 14: 14.0 points at 20 mg and 19.0 points at 50 mg
- CGI-S median reductions at day 14: 1.0 point at 20 mg and 2.0 points at 50 mg
- Generally well tolerated with no serious TEAEs and no ALKS 7290 discontinuations among 50 adults with ADHD
- Phase 2 enrolling approximately 312 participants, with data expected in 2027 and week-four AISRS change as the primary endpoint
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alkermes plc. 8-K filings
Get the next ALKS 8-K as it lands
Follow ALKS for push alerts, or ask the research agent what this filing means.